AIMS/HYPOTHESIS: Type 2 diabetes is a chronic metabolic disorder associated with devastating microvascular complications. Genome-wide association studies have identified more than 60 genetic variants associated with type 2 diabetes and/or glucose and insulin traits, but their role in the progression of diabetes is not established. The aim of this study was to explore whether these variants were also associated with the development of nephropathy in patients with type 2 diabetes. METHODS: We studied 28 genetic variants in 2,229 patients with type 2 diabetes from the local Malmö Scania Diabetes Registry (SDR) published during 2007-2010. Diabetic nephropathy (DN) was defined as micro- or macroalbuminuria and/or end-stage renal disease. Estimated glomerular filtration rate (eGFR) was assessed using the MDRD-4 formula. Replication genotyping of rs1531343 was performed in diabetic (Steno type 2 diabetes [n = 345], Genetics of Diabetes Audit and Research in Tayside Scotland [Go-DARTS] [n = 784]) and non-diabetic (Malmö Preventive Project [n = 2,523], Botnia study [n = 2,247]) cohorts. RESULTS: In the SDR, HMGA2 single-nucleotide polymorphism rs1531343 was associated with DN (OR 1.50, 95% CI 1.20, 1.87, p = 0.00035). In the combined analysis totalling 3,358 patients with type 2 diabetes (n = 1,233 cases, n = 2,125 controls), carriers of the C-allele had a 1.45-fold increased risk of developing nephropathy (95% CI 1.20, 1.75, p = 0.00010). Furthermore, the risk C-allele was associated with lower eGFR in patients with type 2 diabetes (n = 2,499, β ± SEM, -3.7 ± 1.2 ml/min, p = 0.002) and also in non-diabetic individuals (n = 17,602, β ± SEM, -0.008 ± 0.003 ml/min (log( e )), p = 0.006). CONCLUSIONS/ INTERPRETATION: These data demonstrate that the HMGA2 variant seems to be associated with increased risk of developing nephropathy in patients with type 2 diabetes and lower eGFR in both diabetic and non-diabetic individuals and could thus be a common denominator in the pathogenesis of type 2 diabetes and kidney complications.
AIMS/HYPOTHESIS: Type 2 diabetes is a chronic metabolic disorder associated with devastating microvascular complications. Genome-wide association studies have identified more than 60 genetic variants associated with type 2 diabetes and/or glucose and insulin traits, but their role in the progression of diabetes is not established. The aim of this study was to explore whether these variants were also associated with the development of nephropathy in patients with type 2 diabetes. METHODS: We studied 28 genetic variants in 2,229 patients with type 2 diabetes from the local Malmö Scania Diabetes Registry (SDR) published during 2007-2010. Diabetic nephropathy (DN) was defined as micro- or macroalbuminuria and/or end-stage renal disease. Estimated glomerular filtration rate (eGFR) was assessed using the MDRD-4 formula. Replication genotyping of rs1531343 was performed in diabetic (Steno type 2 diabetes [n = 345], Genetics of Diabetes Audit and Research in Tayside Scotland [Go-DARTS] [n = 784]) and non-diabetic (Malmö Preventive Project [n = 2,523], Botnia study [n = 2,247]) cohorts. RESULTS: In the SDR, HMGA2 single-nucleotide polymorphism rs1531343 was associated with DN (OR 1.50, 95% CI 1.20, 1.87, p = 0.00035). In the combined analysis totalling 3,358 patients with type 2 diabetes (n = 1,233 cases, n = 2,125 controls), carriers of the C-allele had a 1.45-fold increased risk of developing nephropathy (95% CI 1.20, 1.75, p = 0.00010). Furthermore, the risk C-allele was associated with lower eGFR in patients with type 2 diabetes (n = 2,499, β ± SEM, -3.7 ± 1.2 ml/min, p = 0.002) and also in non-diabetic individuals (n = 17,602, β ± SEM, -0.008 ± 0.003 ml/min (log( e )), p = 0.006). CONCLUSIONS/ INTERPRETATION: These data demonstrate that the HMGA2 variant seems to be associated with increased risk of developing nephropathy in patients with type 2 diabetes and lower eGFR in both diabetic and non-diabetic individuals and could thus be a common denominator in the pathogenesis of type 2 diabetes and kidney complications.
Authors: M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt Journal: Diabetes Care Date: 1998-04 Impact factor: 19.112
Authors: G Berglund; P Nilsson; K F Eriksson; J A Nilsson; B Hedblad; H Kristenson; F Lindgärde Journal: J Intern Med Date: 2000-01 Impact factor: 8.989
Authors: Monica Fedele; Sabrina Battista; Lawrence Kenyon; Gustavo Baldassarre; Vincenzo Fidanza; Andres J P Klein-Szanto; A F Parlow; Rosa Visone; Giovanna M Pierantoni; Eric Outwater; Massimo Santoro; Carlo M Croce; Alfredo Fusco Journal: Oncogene Date: 2002-05-09 Impact factor: 9.867
Authors: Alyssa Garabedian; Kevin Jeanne Dit Fouque; Prem P Chapagain; Fenfei Leng; Francisco Fernandez-Lima Journal: Nucleic Acids Res Date: 2022-03-21 Impact factor: 19.160
Authors: Nieves González; Isabel Prieto; Laura Del Puerto-Nevado; Sergio Portal-Nuñez; Juan Antonio Ardura; Marta Corton; Beatriz Fernández-Fernández; Oscar Aguilera; Carmen Gomez-Guerrero; Sebastián Mas; Juan Antonio Moreno; Marta Ruiz-Ortega; Ana Belen Sanz; Maria Dolores Sanchez-Niño; Federico Rojo; Fernando Vivanco; Pedro Esbrit; Carmen Ayuso; Gloria Alvarez-Llamas; Jesús Egido; Jesús García-Foncillas; Alberto Ortiz Journal: Oncotarget Date: 2017-03-14
Authors: Harry L Hébert; Bridget Shepherd; Keith Milburn; Abirami Veluchamy; Weihua Meng; Fiona Carr; Louise A Donnelly; Roger Tavendale; Graham Leese; Helen M Colhoun; Ellie Dow; Andrew D Morris; Alexander S Doney; Chim C Lang; Ewan R Pearson; Blair H Smith; Colin N A Palmer Journal: Int J Epidemiol Date: 2018-04-01 Impact factor: 7.196